Literature DB >> 6368354

Renal kallikrein excretion in cirrhotics with ascites: relationship to renal hemodynamics.

R M Pérez-Ayuso, V Arroyo, J Camps, A Rimola, J Costa, J Gaya, F Rivera, J Rodés.   

Abstract

To investigate if the renal kallikrein-kinin system may be involved in the homeostasis of renal perfusion in cirrhosis, urinary kallikrein activity was measured in 11 normal subjects, 31 cirrhotics with ascites and preserved renal plasma flow (548.2 +/- 32.2 ml per min) and glomerular filtration rate (85.8 +/- 3.4 ml per min), and 18 cirrhotics with functional renal failure (renal plasma flow: 229.9 +/- 23.4 ml per min; glomerular filtration rate: 34.9 +/- 3.3 ml per min). Plasma renin activity, plasma norepinephrine concentration and the urinary excretion of prostaglandin E2 were also measured in these subjects. Cirrhotics without renal failure showed a significantly higher renin (4.9 +/- 1.1 ng per ml per hr), norepinephrine (458.2 +/- 50.4 pg per ml), urinary kallikrein (15.4 +/- 1.8 pkat per min) and urinary prostaglandin E2 (0.52 +/- 0.08 ng per min) than did normal subjects (1.08 +/- 0.1 ng per ml per hr, 218.1 +/- 18.2 pg per ml; 8.4 +/- 1.4 pkat per min and 0.24 +/- 0.02 ng per min, respectively). Cirrhotics with renal failure showed a significantly higher renin (16.1 +/- 3.4 ng per ml per hr) and norepinephrine (739.4 +/- 79.2 pg per ml), and a significantly lower urinary kallikrein (5.2 +/- 0.6 pkat per min) and urinary prostaglandin E2 (0.15 +/- 0.02 ng per min) than did normal subjects and cirrhotics without renal failure. Glomerular filtration rate correlated (p less than 0.001) with urinary kallikrein (r = 0.53), urinary prostaglandin E2 (r = 0.55), plasma renin (r = -0.41) and norepinephrine (r = -0.44).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6368354     DOI: 10.1002/hep.1840040213

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE.

Authors:  D Sacerdoti; M Balazy; P Angeli; A Gatta; J C McGiff
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Portal pressure, renal function and hormonal profile after acute and chronic captopril treatment in cirrhosis.

Authors:  F R Ibarra; C Afione; D Garzon; M Barontini; J C Santos; E Arrizurieta
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis.

Authors:  K Lenz; H Hörtnagl; W Druml; G Grimm; A Laggner; B Schneeweisz; G Kleinberger
Journal:  Gut       Date:  1989-01       Impact factor: 23.059

4.  Treatment of ascites in patients with cirrhosis of the liver.

Authors:  V Arroyo; P Ginés; J Rodés
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

Review 5.  Pathophysiology and clinical basis of prevention and treatment of complications of chronic liver disease.

Authors:  S Wagner; H U Lautz; M J Müller; F W Schmidt
Journal:  Klin Wochenschr       Date:  1991-02-06

Review 6.  Aetiology and pathophysiology of chronic liver disorders.

Authors:  J Schölmerich; A Holstege
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 7.  Renal dysfunction associated with liver transplantation.

Authors:  R M Jindal; I Popescu
Journal:  Postgrad Med J       Date:  1995-09       Impact factor: 2.401

Review 8.  Drug administration in chronic liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.228

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.